NRX Pharmaceuticals 주식 (NASDAQ: NRXP)

에 대한 최신 뉴스 NRX Pharmaceuticals (NASDAQ:NRXP) 주식

NRX PHARMACEUTICALS INC

NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals Inc

News

General

SmartStop Self Storage REIT Announces The Acquisition Of A Class A Self-Storage Facility In Vancouver, British Columbia; No Terms Disclosed

<a href="https://www.sec.gov/Archives/edgar/data/1842939/000095017025090015/xage-20250624.htm">https://www.sec.gov/Archives/edgar/data/1842939/000095017025090015/xage-20250624.htm</a>

GBCI

GNTY

Guaranty Bancshares Says If Deal Terminated Under Certain Circumstances, Co To Pay Termination Fee Of $18.5M To Glacier Bancorp

Bit Digital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares are falling in Wednesday&#8217;s after-hours session after the company announced <a href="https://www.benzinga.com/pressreleases/25/06/n46103338/bit-digital-inc-announces-commencement-of-public-offering-of-its-ordinary-shares">a public offering</a>.
What To Know: Bit Digital said it commenced an underwritten public offering of ordinary shares. The company did not provide details of the offering, but said it plans to use net proceeds to purchase Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
In connection with the offering, Bit Digital said it initiated a strategic transition to become a pure-play Ethereum staking and treasury company.
Bit Digital started buying Ethereum in 2022. The company held a total of 24,432.2 ETH as of March 31. Bit Digital also held 417.6 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as of the end of March. The company plans to convert its Bitcoin holdings into Ethereum over time as it winds down its Bitcoin mining operations.
After market close on Wednesday, Bit Digital also announced it confidentially submitted a draft registration statement with the SEC related to a proposed initial public offering of its subsidiary WhiteFiber. The company has not yet determined the number of shares to be offered or the price range for the proposed IPO.
BTBT Price Action: <a href="http://benzinga.com/quote/btbt">Bit Digital shares</a> are down nearly 20% year-to-date. The crypto stock was down 3.40% in after-hours, trading at $2.27 at the time of publication Wednesday, per <a href="http://pro.benzinga.copm">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098386/bitcoin-mining-stock-cleanspark-clsk-is-surging-wednesday-whats-going-on">Bitcoin Mining Stock CleanSpark (CLSK) Is Surging Wednesday: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

$ETH

BTBT

Bit Digital Stock Falls As Company Ditches Bitcoin For Ethereum

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Merger Agreement Deadline Extended To July 8, 2025; Merger Agreement To Terminate On July 8, 2025 If Not Extended

<h3>Gainers</h3>
<ul>
<li>DHI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) stock increased by 7.3% to $2.8 during Wednesday's after-market session. The company's market cap stands at $124.3 million. </li>
<li>Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) shares rose 5.81% to $1.73. The company's market cap stands at $215.5 million. </li>
<li>iOThree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOTR#NASDAQ">IOTR</a>) stock rose 5.2% to $0.41. The market value of their outstanding shares is at $10.7 million. </li>
<li>Starz Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRZ#NASDAQ">STRZ</a>) stock rose 4.98% to $16.86. The market value of their outstanding shares is at $264.1 million. </li>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares moved upwards by 4.84% to $1.73. The company's market cap stands at $86.1 million. </li>
<li>Fast Track (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRK#NASDAQ">FTRK</a>) shares increased by 4.81% to $1.74. The market value of their outstanding shares is at $53.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Beasley Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) stock declined by 10.3% to $3.67 during Wednesday's after-market session. The company's market cap stands at $7.3 million. </li>
<li>Grupo Televisa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TV#NYSE">TV</a>) shares decreased by 4.9% to $2.33. The market value of their outstanding shares is at $2.6 billion. </li>
<li>EPWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) shares decreased by 4.05% to $0.55. The company's market cap stands at $11.0 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares declined by 3.68% to $2.62. The market value of their outstanding shares is at $8.9 million. </li>
<li>CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) stock decreased by 3.66% to $5.33. The market value of their outstanding shares is at $329.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

BBGI

CDLX

CURI

EPWK

FTRK

IOTR

SEAT

STRZ

11 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 19.6% to $0.29 during Wednesday's after-market session. The company's market cap stands at $2.3 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) stock moved upwards by 19.19% to $0.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares increased by 14.19% to $1.85. The market value of their outstanding shares is at $2.8 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock rose 13.54% to $0.62. The company's market cap stands at $39.7 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares increased by 8.06% to $6.7. The company's market cap stands at $83.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 7.96% to $0.34. The company's market cap stands at $1.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock declined by 32.5% to $0.52 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock fell 7.81% to $0.65. The market value of their outstanding shares is at $3.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 7.65% to $1.45. The market value of their outstanding shares is at $3.2 million. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) stock fell 7.5% to $1.11. The company's market cap stands at $11.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 7.12% to $2.35. The company's market cap stands at $3.4 million. </li>
<li>Evaxion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares decreased by 7.02% to $2.41. The company's market cap stands at $15.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ADTX

AEMD

EVAX

PSTV

RVPH

SXTP

UNCY

XTLB

ZVSA

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) shares increased by 9.2% to $19.25 during Wednesday's after-market session. The company's market cap stands at $1.1 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock moved upwards by 8.73% to $1.12. The company's market cap stands at $18.0 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock rose 5.59% to $0.22. The company's market cap stands at $18.5 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) stock rose 5.29% to $1.79. The company's market cap stands at $56.8 million. </li>
<li>LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) stock rose 4.89% to $9.0. The market value of their outstanding shares is at $1.5 billion. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares rose 4.28% to $1.46. The company's market cap stands at $9.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) stock decreased by 6.7% to $39.5 during Wednesday's after-market session. The market value of their outstanding shares is at $6.2 billion. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares fell 5.69% to $0.32. The market value of their outstanding shares is at $5.7 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares declined by 5.3% to $0.32. The market value of their outstanding shares is at $71.2 million. </li>
<li>WF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) stock fell 5.15% to $2.58. The company's market cap stands at $20.0 million. </li>
<li>Roma Green Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) stock decreased by 5.13% to $2.96. The company's market cap stands at $44.0 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares decreased by 4.61% to $0.19. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

DXST

HOVR

HTOO

KTOS

LNZA

MLKN

ROMA

ZBAI

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) shares rose 10.2% to $0.93 during Wednesday's after-market session. The company's market cap stands at $72.0 million. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) stock increased by 5.59% to $0.94. The company's market cap stands at $2.7 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares moved upwards by 5.5% to $2.3. The market value of their outstanding shares is at $1.0 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock increased by 4.6% to $3.18. The market value of their outstanding shares is at $16.0 million. </li>
<li>Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) shares increased by 4.49% to $1.86. The company's market cap stands at $51.2 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock moved upwards by 4.11% to $0.78. The company's market cap stands at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares declined by 7.4% to $1.5 during Wednesday's after-market session. The market value of their outstanding shares is at $46.1 million. </li>
<li>Maris Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>) stock fell 4.99% to $2.67. The market value of their outstanding shares is at $22.1 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock declined by 3.96% to $2.43. The market value of their outstanding shares is at $1.0 billion. </li>
<li>GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) shares fell 3.49% to $3.21. The company's market cap stands at $93.9 million. </li>
<li>Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) stock fell 3.4% to $2.27. The company's market cap stands at $508.8 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares declined by 3.26% to $1.19. The company's market cap stands at $16.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMOD

BTCT

GSIT

LPSN

MOVE

MRIN

MTEK

Next Technology Holding Inc. - Ordinary Shares

NXTT

SVRE

UPLD

XTKG

12 Information Technology Stocks Moving In Wednesday's After-Market Session

AGAE

Allied Gaming & Entertainment Announces Receipt Of Non-Compliance Notice From Nasdaq On June 18, 2025

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is set to give its latest quarterly earnings report on Thursday, 2025-06-26. Here's what investors need to know before the announcement.
Analysts estimate that Orion Energy Sys will report an earnings per share (EPS) of $-0.03. 
Investors in Orion Energy Sys are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.04 in the last quarter, leading to a 1.85% drop in the share price on the following day.
Here's a look at Orion Energy Sys's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.11</td>
<td>-0.12</td>
<td>0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885274_0.png" alt="eps graph" />
<h3>Market Performance of Orion Energy Sys's Stock</h3>
Shares of Orion Energy Sys were trading at $0.5919 as of June 24. Over the last 52-week period, shares are down 51.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/OESX/earnings">To track all earnings releases for Orion Energy Sys visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

OESX

Insights into Orion Energy Sys's Upcoming Earnings

HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect HIVE Digital Technologies to report an earnings per share (EPS) of $-0.11.
Anticipation surrounds HIVE Digital Technologies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 1.1% increase in the share price on the following day.
Here's a look at HIVE Digital Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.01</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.01</td>
<td>-0.06</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-8.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885257_0.png" alt="eps graph" />
<h3>Performance of HIVE Digital Technologies Shares</h3>
Shares of HIVE Digital Technologies were trading at $1.85 as of June 24. Over the last 52-week period, shares are down 43.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HIVE/earnings">To track all earnings releases for HIVE Digital Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HIVE

HIVE Digital Technologies's Earnings: A Preview

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Concentrix will report an earnings per share (EPS) of $2.75.
Anticipation surrounds Concentrix's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.20, leading to a 42.38% increase in the share price the following trading session.
Here's a look at Concentrix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.59</td>
<td>3.01</td>
<td>2.93</td>
<td>2.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.79</td>
<td>3.26</td>
<td>2.87</td>
<td>2.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>42.0%</td>
<td>3.0%</td>
<td>-19.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885251_0.png" alt="eps graph" />
<h3>Performance of Concentrix Shares</h3>
Shares of Concentrix were trading at $54.08 as of June 24. Over the last 52-week period, shares are down 13.7%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Concentrix</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Concentrix.
Analysts have provided Concentrix with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $58.0, suggesting a potential 7.25% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Verra Mobility, CSG Systems Intl and TaskUs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Verra Mobility, with an average 1-year price target of $26.88, suggesting a potential 50.3% downside.</li>
<li>Analysts currently favor an Neutral trajectory for CSG Systems Intl, with an average 1-year price target of $58.0, suggesting a potential 7.25% upside.</li>
<li>Analysts currently favor an Neutral trajectory for TaskUs, with an average 1-year price target of $16.5, suggesting a potential 69.49% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Verra Mobility, CSG Systems Intl and TaskUs, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrix</td>
<td>Neutral</td>
<td>-1.27%</td>
<td>$855.90M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Verra Mobility</td>
<td>Outperform</td>
<td>6.45%</td>
<td>$210.44M</td>
<td>11.45%</td>
</tr>
<tr>
<td>CSG Systems Intl</td>
<td>Neutral</td>
<td>1.46%</td>
<td>$144.96M</td>
<td>5.70%</td>
</tr>
<tr>
<td>TaskUs</td>
<td>Neutral</td>
<td>22.12%</td>
<td>$106.61M</td>
<td>4.16%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Concentrix ranks in the middle among its peers for revenue growth, with a slight decline. It is at the bottom for gross profit, indicating lower profitability. However, Concentrix is at the top for return on equity, showing strong performance in generating profits relative to shareholders' equity.
<h3>All You Need to Know About Concentrix</h3>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Key Indicators: Concentrix's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Concentrix faced challenges, resulting in a decline of approximately -1.27% in revenue growth as of 28 February, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Concentrix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.82%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Concentrix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Concentrix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Concentrix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.22.
<a href="https://www.benzinga.com/quote/CNXC/earnings">To track all earnings releases for Concentrix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNXC

Preview: Concentrix's Earnings

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Enerpac Tool Group to report an earnings per share (EPS) of $0.47.
Investors in Enerpac Tool Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 8.39% increase in the share price on the subsequent day.
Here's a look at Enerpac Tool Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.41</td>
<td>0.53</td>
<td>0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.40</td>
<td>0.50</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885242_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enerpac Tool Group were trading at $43.36 as of June 24. Over the last 52-week period, shares are up 13.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EPAC/earnings">To track all earnings releases for Enerpac Tool Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPAC

Earnings Preview: Enerpac Tool Group

Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Walgreens Boots Alliance to report an earnings per share (EPS) of $0.34.
Investors in Walgreens Boots Alliance are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 1.79% increase in the share price on the following day.
Here's a look at Walgreens Boots Alliance's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.52</td>
<td>0.37</td>
<td>0.36</td>
<td>0.71</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.63</td>
<td>0.51</td>
<td>0.39</td>
<td>0.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>28.000000000000004%</td>
<td>6.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885233_0.png" alt="eps graph" />
<h3>Walgreens Boots Alliance Share Price Analysis</h3>
Shares of Walgreens Boots Alliance were trading at $11.35 as of June 24. Over the last 52-week period, shares are down 7.22%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/WBA/earnings">To track all earnings releases for Walgreens Boots Alliance visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Walgreens Boots Alliance's Earnings Forecast

In the current market session, Bank of New York Mellon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) stock price is at $90.00, after a 1.32% drop. However, over the past month, the company's stock increased by 1.35%, and in the past year, by 51.16%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750885228_0.png" alt="Past Year Chart" />

<h3>Comparing Bank of New York Mellon P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Bank of New York Mellon has a lower P/E than the aggregate P/E of 34.88 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750885228_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Bank of New York Mellon

Acuity Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Acuity Brands will report an earnings per share (EPS) of $4.49.
Anticipation surrounds Acuity Brands's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 9.2% drop in the share price on the following day.
Here's a look at Acuity Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.70</td>
<td>3.89</td>
<td>4.28</td>
<td>4.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.73</td>
<td>3.97</td>
<td>4.30</td>
<td>4.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885225_0.png" alt="eps graph" />
<h3>Acuity Brands Share Price Analysis</h3>
Shares of Acuity Brands were trading at $284.44 as of June 24. Over the last 52-week period, shares are up 18.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on Acuity Brands</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Acuity Brands.
The consensus rating for Acuity Brands is Neutral, derived from 6 analyst ratings. An average one-year price target of $295.0 implies a potential 3.71% upside.
<h3>Comparing Ratings with Competitors</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Nextracker, Regal Rexnord and Generac Hldgs, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Nextracker, with an average 1-year price target of $62.75, suggesting a potential 77.94% downside.</li>
<li>Analysts currently favor an Buy trajectory for Regal Rexnord, with an average 1-year price target of $148.57, suggesting a potential 47.77% downside.</li>
<li>Analysts currently favor an Buy trajectory for Generac Hldgs, with an average 1-year price target of $156.62, suggesting a potential 44.94% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Nextracker, Regal Rexnord and Generac Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acuity</td>
<td>Neutral</td>
<td>11.08%</td>
<td>$468M</td>
<td>3.11%</td>
</tr>
<tr>
<td>Nextracker</td>
<td>Outperform</td>
<td>25.50%</td>
<td>$305.69M</td>
<td>10.33%</td>
</tr>
<tr>
<td>Regal Rexnord</td>
<td>Buy</td>
<td>-8.37%</td>
<td>$527.60M</td>
<td>0.90%</td>
</tr>
<tr>
<td>Generac Hldgs</td>
<td>Buy</td>
<td>5.94%</td>
<td>$371.99M</td>
<td>1.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Acuity Brands ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
<h3>Delving into Acuity Brands's Background</h3>
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
<h3>Acuity Brands: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Acuity Brands's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.08% as of 28 February, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Acuity Brands's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.7%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acuity Brands's ROE excels beyond industry benchmarks, reaching 3.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acuity Brands's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<a href="https://www.benzinga.com/quote/AYI/earnings">To track all earnings releases for Acuity Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Acuity Brands's Quarterly Earnings

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 10 years by 6.73% on an annualized basis producing an average annual return of 18.16%. Currently, RBC Bearings has a market capitalization of $11.97 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 10 years ago, it would be worth $5,331.61 today based on a price of $380.57 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750885217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Vor Bio Announces $175M Private Placement Of 700M Warrants At A Price Of $0.25 Per Warrant

<a href="https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm">https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm</a>

Offerings

BCLI

Brainstorm Cell Therapeutics Files Prospectus For Offer & Sale Of Up To 2.8M Shares Of Common Stock By Selling Stockholder

-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis
-RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties
-Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS (also known as BAFF) and APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.

Biotech

Contracts

Management

Vor Bio Licenses Ex-Greater China Rights To Telitacicept From RemeGen In $125M Deal With Milestones Over $4B; Appoints Jean-Paul Kress As CEO And Chairman

Press Releases

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

Small Cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

"Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz"

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

AIFF

ARAI

CTOR

ILMN

NRXP

PNPNF

PRSO

SNYR

TSXV:PNPN

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Eyenovia

Grace Therapeutics

Ikena Oncology

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

Scilex Holding

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

D. Boral Capital

Ascendiant Capital

BTIG

HC Wainwright & Co.

EF Hutton

Screenshot 2024-04-10 at 5.50.02 PM

NRX&#39;s (NASDAQ: NRXP) NMDA Modification Therapy And Its Multiple Applications From Mental Health To Chronic Pain

Comments

NRX Pharmaceuticals

뉴스

에 대한 최신 뉴스 NRX Pharmaceuticals (NASDAQ:NRXP) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌